KEY POINTS
- This systematic review evaluated randomized controlled trials of radiotherapy for basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (SCC), melanoma and Merkel cell carcinoma (MCC). Searches of MEDLINE, Embase and CENTRAL identified 13 eligible randomized trials involving fewer than 2,500 patients, with only four studies published within the preceding decade. The evidence comprised five BCC trials, one mixed BCC/SCC trial, one SCC trial, five melanoma trials and one MCC trial.
- In operable facial BCC, a randomized comparison of surgery versus radiotherapy demonstrated fewer four-year recurrences after surgery (1/174 vs 11/173), alongside better cosmetic outcomes. Another randomized study found substantially lower two-year recurrence after RT than cryotherapy (4% vs 39%), although both trials reflect historical treatment techniques and may not represent modern image-guided or highly conformal approaches.
- Randomized fractionation evidence for skin cancer remains particularly outdated. In one trial comparing 21–22.5 Gy in one fraction, 40 Gy in four fractions and 48 Gy in eight fractions, three-year recurrence rates were 2%, 2% and 6%, respectively, but skin necrosis occurred in 10%, 5% and 1% (p<0.01), suggesting that extreme hypofractionation may compromise tissue tolerance despite apparently similar tumor control.
- For high-risk cutaneous head and neck SCC, the randomized TROG 05.01 trial compared postoperative RT alone with postoperative carboplatin-based chemoradiotherapy. Five-year locoregional recurrence was approximately 17% with RT versus 13% with chemoradiotherapy, while overall survival was 76% versus 79%; neither difference was statistically significant, providing no demonstrated benefit from adding concurrent carboplatin.
- In high-risk stage III melanoma after lymphadenectomy, adjuvant regional nodal RT reduced six-year nodal-field recurrence from 36% to 21% (HR 0.52, 95% CI 0.31–0.88) but did not improve overall survival and increased severe toxicity. Other melanoma trials were smaller or underpowered, including investigations of postoperative RT for neurotropic head and neck melanoma and definitive RT versus imiquimod for lentigo maligna.
- The only identified randomized trial addressing regional irradiation in resected stage I MCC enrolled 83 of 210 planned patients before early closure. Adding elective nodal irradiation to tumor-bed RT reduced three-year regional recurrence from 17% to 0%, without demonstrating an overall survival benefit; changes in sentinel-node staging during recruitment further limit direct application to modern management.
- Across all 13 trials, evidence quality was constrained by small patient numbers, heterogeneous interventions, incomplete reporting of dose and treatment techniques, and inconsistent assessment of toxicity, cosmesis and patient-reported outcomes. The review identified particularly important gaps in definitive RT for cutaneous SCC, modern hypofractionated schedules, and the integration of RT with immunotherapy and targeted agents, emphasizing that lack of randomized evidence should not be confused with evidence of ineffectiveness.
CLINICAL TAKEAWAY
Despite widespread clinical use, radiotherapy for cutaneous malignancies remains supported by relatively little randomized evidence, particularly for contemporary techniques and combined-modality treatment. Existing trials inform selected decisions regarding surgery, fractionation and postoperative regional treatment, but modern randomized studies incorporating toxicity, cosmesis and patient-reported outcomes are needed to define optimal practice.